Treatment with Growth Hormone and Luteinizing Hormone Releasing Hormone Analog Improves Final Adult Height in Children with Congenital Adrenal Hyperplasia
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Final adult height is often compromised in children with congenital adrenal hyperplasia (CAH). This study examines the impact of GH and LHRH analog (LHRHa) on final adult height in patients with CAH due to 21-hydroxylase deficiency. Fourteen patients with CAH (eight males, six females) predicted to be more than 1.0 sd below their midparental target height received GH and LHRHa until final height. Each patient was matched at the start of GH therapy to a CAH patient treated only with glucocorticoids according to type of CAH, sex, and chronological age. Mean age, bone age, height, height prediction, and target height were the same in both groups at the beginning of GH therapy. Mean duration of GH treatment was 4.4 +/- 1.5 yr. Mean duration of LHRHa therapy was 4.2 +/- 2.0 yr. In the treatment group, final height sd score of -0.4 + 0.8 was significantly greater than both the initial prediction of -1.5 +/- 0.9 (P < 0.0001) and the final height sd score of the untreated group of -1.4 +/- 1.1 (P = 0.01). Our results indicate that the combination of GH and LHRHa improves final adult height in patients with CAH.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Fourteen patients treated with growth hormone and GnRH plus conventional therapy for ;4 years had improved adult height (+1.1 SDS) (323) compared with historical controls with CAH treated with conventional therapy alone (SDS of 20.4 vs 21.4,P = 0.01).”
From Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society* Clinical Practice Guideline (2018) · cites this paper as [323]
Citations
Cites
RADIOGRAPHIC ATLAS OF SKELETAL DEVELOPMENT OF THE HAND AND WRIST
GREULICH, W. W., & PYLE, S. I. (1959) · The American Journal Of The Medical Sciences · doi:10.1097/00000441-195909000-00030 · Cited by 5,585
Congenital adrenal hyperplasia due to 21-hydroxylase deficiency*
White, P. C., & Speiser, P. W. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.3.0398 · Cited by 1,432
Bayley, N., & Pinneau, S. R. (1952) · The Journal of Pediatrics · doi:10.1016/s0022-3476(52)80205-7 · Cited by 1,196 · cited 2×
“Predicted adult height was calculated using BA and height according to the Bayley-Pinneau method (38).”
MethodClinical longitudinal standards for height and height velocity for North American children
Tanner, J. M., & Davies, P. S. W. (1985) · The Journal of Pediatrics · doi:10.1016/s0022-3476(85)80501-1 · Cited by 1,092 · cited 2×
“However, the groups were still similar with regards to onset of puberty in that the majority of subjects (10 of 14 in each group) had early onset of puberty (before age 10 in girls and age 11 in boys) (41).”
BackgroundStandards for Children's Height at Ages 2-9 Years Allowing for Height of Parents
Tanner, J. M., Goldstein, H., & Whitehouse, R. H. (1970) · Archives of Disease in Childhood · doi:10.1136/adc.45.244.755 · Cited by 812
Tanner, J. M., Whitehouse, R. H., Marshall, W. A., & Carter, B. S. (1975) · Archives of Disease in Childhood · doi:10.1136/adc.50.1.14 · Cited by 348
GROWTH SUPPRESSION BY GLUCOCORTICOID THERAPY
Allen, D. B. (1996) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70348-0 · Cited by 227 · cited 1×
“activity, as well as bone formation and collagen formation, processes essential for normal growth (28).”
BackgroundThe suppression of androgen secretion by cortisone in a case of congenital adrenal hyperplasia.
Wilkins, L., Ra, L., Klein, R., & ROSEMBERG, E. (1950) · PubMed · Cited by 218
Long Term Outcome in Adult Males with Classic Congenital Adrenal Hyperplasia1
Cabrera, M. S., Vogiatzi, M. G., & New, M. I. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.7.7668 · Cited by 204
Self-citationPESCOVITZ, O. H., HENCH, K. D., BARNES, K. M., LORIAUX, D. L., & CUTLER, G. B. (1988) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-67-3-474 · Cited by 198
Cited by
Speiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2631 · Cited by 1,468
“When doses exceed 20 mg/m · d in infants and 15– 17 mg/m · d in adolescents, there is loss of height SD score (SDS) and shorter adult height SDS (123,124,125,126,127).”
InfluentialSpeiser, P. W., Arlt, W., Auchus, R. J., Baskin, L. S., Conway, G. S., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Murad, M. H., Oberfield, S. E., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01865 · Cited by 1,234
Consensus Statement on the Use of Gonadotropin-Releasing Hormone Analogs in Children
Carel, J.-C., Eugster, E. A., Rogol, A., Ghizzoni, L., Palmert, M. R., & on behalf of the members of the ESPE-LWPES GnRH Analogs Consensus Conference Group (2009) · Pediatrics · doi:10.1542/peds.2008-1783 · Cited by 817
Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management
Claahsen - van der Grinten, H. L., Speiser, P. W., Ahmed, S. F., Arlt, W., Auchus, R. J., Falhammar, H., Flück, C. E., Guasti, L., Huebner, A., Kortmann, B. B. M., et al. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab016 · Cited by 556
Nonclassical 21-Hydroxylase Deficiency
New, M. I. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1645 · Cited by 315
Self-citationPW, S., W, A., RJ, A., LS, B., GS, C., DP, M., HFL, M.-B., WL, M., MH, M., SE, O., et al. (2019) · Yearbook of Paediatric Endocrinology · doi:10.1530/ey.16.8.5 · Cited by 300
Adult Height in Patients with Congenital Adrenal Hyperplasia: A Systematic Review and Metaanalysis
Muthusamy, K., Elamin, M. B., Smushkin, G., Murad, M. H., Lampropulos, J. F., Elamin, K. B., Abu Elnour, N. O., Gallegos-Orozco, J. F., Fatourechi, M. M., Agrwal, N., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2616 · Cited by 182
Adrenal Steroidogenesis and Congenital Adrenal Hyperplasia
Turcu, A. F., & Auchus, R. J. (2015) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2015.02.002 · Cited by 177
“Growth hormone, with or without a GnRH agonist, improved final height in some studies.(116,117) In addition, GnRH antagonist has been successful in improving height in children with 21OHD and precocious puberty.”
BackgroundFalhammar, H., Filipsson, H., Holmdahl, G., Janson, P.-O., Nordenskjöld, A., Hagenfeldt, K., & Thorén, M. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1350 · Cited by 167
Clinical perspectives in congenital adrenal hyperplasia due to 11β-hydroxylase deficiency
Bulsari, K., & Falhammar, H. (2016) · Endocrine · doi:10.1007/s12020-016-1189-x · Cited by 149
Management of the child with congenital adrenal hyperplasia
Hindmarsh, P. C. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.10.010 · Cited by 120
Riepe, F. G., & Sippell, W. G. (2007) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-007-9053-1 · Cited by 108
“published a non-randomized trial with GH and GnRHa in 28 21-OHD patients of comparable age, bone age, height, target height, predicted height and disease severity [86].”
BackgroundGonadotropin releasing hormone agonists: Expanding vistas
Magon, N. (2011) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.85575 · Cited by 110
“They have been used in management of severe cases of congenital adrenal hyperplasia (CAH) and combination of GH and GnRH-a have been found to improve final adult height in patients with CAH.”
BackgroundRecommendations for treatment of nonclassic congenital adrenal hyperplasia (NCCAH): An update
Trapp, C. M., & Oberfield, S. E. (2012) · Steroids · doi:10.1016/j.steroids.2011.12.009 · Cited by 81
“Further, treatment with GnRH analogs and GH prescription if begun before age 12 has resulted in attainment of target height, as demonstrated by Lin-Su et al [42].”
MethodFinal Adult Height in Children with Congenital Adrenal Hyperplasia Treated with Growth Hormone
Lin-Su, K., Harbison, M. D., Lekarev, O., Vogiatzi, M. G., & New, M. I. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2699 · Cited by 75
Self-citationThe next 150 years of congenital adrenal hyperplasia
Turcu, A. F., & Auchus, R. J. (2015) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2015.05.013 · Cited by 70
46,XX DSD: the masculinised female
Auchus, R. J., & Chang, A. Y. (2010) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.11.001 · Cited by 67
Steroid 21 Hydroxylase Deficiency Congenital Adrenal Hyperplasia
Nimkarn, S., Lin‐Su, K., & New, M. I. (2011) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2011.07.012 · Cited by 67
Self-citationNonclassic adrenal hyperplasia
Speiser, P. (2008) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-008-9097-x · Cited by 68
“There are limited data demonstrating efficacy of multi-drug regimens involving growth hormone, and GnRH analogs [ 52 ], or aromatase inhibitors and androgen blockers [53], in addition to glucocorticoids, and these other drugs are not indicated for standard care.”
BackgroundLivadas, S., & Bothou, C. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00366 · Cited by 57
“Another important consideration regards cases of concomitant GH deficiency in the event that treatment with GnRH analogs and GH prescription resulted in attainment of target height (52).”
BackgroundCongenital adrenal hyperplasia – pharmacologic interventions from the prenatal phase to adulthood
Claahsen-van der Grinten, H. L., Stikkelbroeck, N. M. M. L., Otten, B. J., & Hermus, A. R. M. M. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.05.004 · Cited by 53
Steroid 21 hydroxylase deficiency congenital adrenal hyperplasia
Nimkarn, S., Lin-Su, K., & New, M. I. (2009) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2009.08.001 · Cited by 52
Self-citationThe Adrenal Cortex and its Disorders
Miller, W. L. (2009) · Brook's Clinical Pediatric Endocrinology · doi:10.1002/9781444316728.ch13 · Cited by 50
Haddad, N. G., & Eugster, E. A. (2019) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2019.04.007 · Cited by 60
Novel approaches to short stature therapy
Wit, J. M., & Oostdijk, W. (2015) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2015.01.003 · Cited by 45
21-Hydroxylase-Deficient Congenital Adrenal Hyperplasia
Nimkarn, S., Gangishetti, P. K., Yau, M., & New, M. I. (2016) · Cited by 41
Self-citationGüven, A., Cebeci, A. N., & Hancili, S. (2015) · HORMONES · doi:10.14310/horm.2002.1555 · Cited by 39
Congenital Adrenal Hyperplasia: Diagnosis, Evaluation, and Management
Antal, Z., & Zhou, P. (2009) · Pediatrics in Review · doi:10.1542/pir.30-7-e49 · Cited by 36
Schaeffer, T. L., Tryggestad, J. B., Mallappa, A., Hanna, A., Krishnan, S., Chernausek, S. D., Chalmers, L. J., Reiner, W. G., Kropp, B. P., & Wisniewski, A. B. (2010) · International Journal of Pediatric Endocrinology · doi:10.1155/2010/692439 · Cited by 45
“Thoughmodest effects have been reported [45], such treatment is considered experimental at this time [46].”
BackgroundHoepffner, W., Kaufhold, A., Willgerodt, H., & Keller, E. (2008) · Hormone Research in Paediatrics · doi:10.1159/000129677 · Cited by 34
“the additional use of growth hormone, and/or GnRH analogs, antiandrogens and aromatase blockers [”
Nimkarn, S., New, M. I., & Lin-Su, K. (2007) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem.2007.20.8.883 · Cited by 29
Self-citationGrowth and Reproductive Outcomes in Congenital Adrenal Hyperplasia
Nebesio, T. D., & Eugster, E. A. (2010) · International Journal of Pediatric Endocrinology · doi:10.1155/2010/298937 · Cited by 34
“In a nonrandomized study of 14 patients with CAH who received both GH and a GnRH analog, FH and gain in height were statistically better when compared to a similar, untreated group [53].”
Validation of automatic bone age determination in children with congenital adrenal hyperplasia
Martin, D. D., Heil, K. F., Heckmann, C., Zierl, A., Schaefer, J. F., Ranke, M. B., & Binder, G. (2013) · Pediatric Radiology · doi:10.1007/s00247-013-2744-8 · Cited by 29
“Experimental therapeutic approaches include addition of growth hormone [12] or peripheral inhibition of androgen activity and estrogen production.”
BackgroundThe Adrenal Cortex and Its Disorders
Miller, W. L., Achermann, J. C., & Flück, C. E. (2008) · Elsevier eBooks · doi:10.1016/b978-141604090-3.50017-x · Cited by 33
Should Skeletal Maturation Be Manipulated for Extra Height Gain?
Wit, J. M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.812196 · Cited by 30
“In the treatment group, AH SDS was 1 SD greater than both the initial PAH SDS and AH SDS of the untreated group (95) (LoE 3).”
BackgroundGrowth in Patients with Classic Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency
Dörr, H. G. (2007) · Hormone Research in Paediatrics · doi:10.1159/000110587 · Cited by 31
“Recently, adult height data were published in a small group of 14 patients with CAH (8 males, 6 females) who received human growth hormone 0.3 mg/kg/week and the GnRH analogue leuprolide acetate 300 μg/kg intramuscularly every 28 days. The mean duration was 4.4 years for GH therapy and 4.2 years for GnRH analogue ther…”
BackgroundInfluentialCongenital Adrenal Hyperplasia Owing to 21-Hydroxylase Deficiency
New, M. I., Lekarev, O., Mancenido, D., Parsa, A. A., & Yuen, T. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-416006-4.00003-x · Cited by 29
Self-citationSarafoglou, K., Gonzalez‐Bolanos, M. T., Zimmerman, C. L., Boonstra, T., Yaw Addo, O., & Brundage, R. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.424 · Cited by 20
“Puberty was being suppressed with histrelin acetate in 6 patients on hydrocortisone tablets (5 females, 2 males) with significantly advanced bone age (>2 SD).(19,20) Puberty was adequately suppressed as indicated by clinical and hormonal measures.”
BackgroundLimb lengthening in children with Russell–Silver syndrome: A comparison to other etiologies
Goldman, V., McCoy, T. H., Harbison, M. D., Fragomen, A. T., & Rozbruch, S. R. (2013) · Journal of Children s Orthopaedics · doi:10.1007/s11832-012-0474-3 · Cited by 19
Self-citationKareva, M., & Чугунов, І. (2014) · Problems of Endocrinology · doi:10.14341/probl201460242-50 · Cited by 25
Loechner, K. J., McLaughlin, J. T., & Calikoglu, A. S. (2010) · International Journal of Pediatric Endocrinology · doi:10.1155/2010/670960 · Cited by 18
“[47] demonstrated, in a subsequent trial in which fourteen children with CAH were followed to final adult height, that combination treatment with leuprolide acetate and GH can result in an improved final adult height by approximately 1SD compared to matched control children who received standard therapy.”
BackgroundCordeiro, G. V., Silva, I. N., Goulart, E. M. A., das Chagas, A. J., & Kater, C. E. (2013) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302013000200005 · Cited by 21
“Alternative treatments, such as the use of growth hormone associated to puberty inhibitors, in addition to anti-estrogen therapy, were used in an attempt to improve height prognosis in these patients (14-17).”
MethodAdrenogenitales Syndrom und Wachstumshormonmangel: Betreuung beim Übergang zum Erwachsenenalter
Dörr, H. G., & Schöfl, C. (2009) · Der Internist · doi:10.1007/s00108-009-2401-3 · Cited by 17
Ergun-Longmire, B., & Wajnrajch, M. P. (2013) · Europe PMC (PubMed Central) · Cited by 17
Longui, C. A., Kochi, C., Calliari, L. E., Modkovski, M. B. R., Soares, M., Alves, É. F., Prudente, F. V. B., & Monte, O. (2011) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302011000800023 · Cited by 16
“More recently, the treatment with human growth hormone (GH) has been demonstrated to be able to improve growth velocity and final height in this condition (7-9).”
BackgroundGrowth characteristics in children with congenital adrenal hyperplasia
Alzanbagi, M. A., Milyani, A. A., & Al-Agha, A. E. (2018) · Saudi Medical Journal · doi:10.15537/smj.2018.7.22193 · Cited by 17
Nonclassic 21-hydroxylase deficiency
New, M. I. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2006.03.005 · Cited by 15
Self-citationManagement of congenital adrenal hyperplasia: beyond conventional glucocorticoid therapy
Khattab, A., & Marshall, I. H. (2019) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000780 · Cited by 14
“com approach is that GnRHa suppression of the HPG axis can eliminate the effect of pubertal sex hormones on epiphyses with concomitant use of growth hormone to counter GnRHa-associated growth deceleration [24,25].”
Self-citationCongenital adrenal hyperplasia—glucocorticoids and height
Speiser, P. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.242 · Cited by 13
Medical treatment of classic and nonclassic congenital adrenal hyperplasia
Speiser, P. W. (2011) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-8002-1_9 · Cited by 10
“1 SD) [20].”
Shaikh, A. M. A., Alghanmi., Y., Awidah, S., Bahha, A., Ahmed, M., & Soliman, A. T. (2019) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_99_19 · Cited by 12
The Use of Gonadotropin-Releasing Hormone Analogs beyond Precocious Puberty
Eugster, E. A. (2015) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2015.05.031 · Cited by 10
“In one small study, 14 patients predicted to be >1 SD below target height were treated with a GnRHa and GH for 4 years.(34) They achieved an adult height 1 SDS greater than that demonstrated by a matched untreated historical control group.”
BackgroundWang, X., Mao, J., Li, S., Zhao, Y., Nie, M., Yu, B., Gao, Y., Lü, L., & Wu, X. (2020) · Endocrine Practice · doi:10.4158/ep-2019-0610 · Cited by 11
Indications for growth hormone therapy
Butler, G. E. (2007) · Paediatrics and Child Health · doi:10.1016/j.paed.2007.06.008 · Cited by 8
Genotype and clinical outcomes in children with congenital adrenal hyperplasia
Yoon, J. Y., & Cheon, C. K. (2020) · Pediatrics International · doi:10.1111/ped.14478 · Cited by 8
Chalmers, L. J., Casas, L., New, M. I., & Blackett, P. R. (2006) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem.2006.19.10.1251 · Cited by 7
Self-citationLiu, X., Liu, F., Qi, Y., Han, X., Ma, S., & Zheng, R. (2025) · BMC Pediatrics · doi:10.1186/s12887-025-05703-8 · Cited by 6
“Numerous studies have shown that CAH patients are approximately 10 cm shorter than their parent-based target height [7, 8].”
Bird's-Eye View of GnRH Analog use in a Pediatric Endocrinology Referral Center
Watson, S. E., Greene, A., Lewis, K., & Eugster, E. A. (2015) · Endocrine Practice · doi:10.4158/ep14412.or · Cited by 5
Bajpai, A., Kabra, M., & Menon, P. S. N. (2006) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem.2006.19.6.855 · Cited by 6
Vieira, A., Paiva, S., Baptista, C. F., Ruas, L., Silva, J., Gonçalves, J., Carrilho, F., & Carvalheiro, M. C. (2011) · Acta Médica Portuguesa · doi:10.20344/amp.338 · Cited by 6
Völkl, T. M. K., Rauh, M., Schöfl, C., & Dörr, H. G. (2011) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2011.05.001 · Cited by 5
“Two studies on rhGH treatment with or without combination with gonadotropinreleasing hormone analog therapy show evidence of improvement of growth rate and height prediction and final heights in children with classic CAH [63,64].”
BackgroundBadawi, N. E., Fawaz, L., Amin, A., Kamel, A., & Arafa, N. (2021) · Endokrynologia Polska · doi:10.5603/ep.a2021.0039 · Cited by 5
“B&P is usually intended for use in healthy children, but studies have employed this method to evaluate the effect of growth-promoting therapies in patients with CAH [27].”
MethodAureli, A., Bocchini, S., Mariani, M., Crinò, A., Cappa, M., & Fintini, D. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1148318 · Cited by 4
Hiperplasia congénita da suprarrenal não clássica – aspetos relevantes para a prática clínica
Azevedo, T., Martins, T., Lemos, M. C., & Rodrigues, F. (2014) · Revista Portuguesa de Endocrinologia Diabetes e Metabolismo · doi:10.1016/j.rpedm.2013.12.001 · Cited by 10
Treatment of Gonadotropin-Dependent Precocious Puberty
Nabhan, Z. M., & Walvoord, E. C. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-499-5_16 · Cited by 3
Hernández, M., Carmona, J. Y., López, C. B., & Bouthelier, R. G. (2007) · Anales de Pediatría · doi:10.1016/s1695-4033(07)70576-3 · Cited by 3
Latrech, H., & Gaouzi, A. (2015) · Pan African Medical Journal · doi:10.11604/pamj.2015.20.162.5905 · Cited by 3
“Cette possibilité thérapeutique, utilisée hors AMM, doit être instaurée au bon moment alors qu'il reste encore un potentiel de croissance satisfaisant [4, 8, 9, 11,12].”
BackgroundInfluentialDéficit de 21-hidroxilasa: aspectos actuales
Rodriguez-Arnao, M. D., Rodríguez, A., Badillo, K., Velasco, A. M., Dulín, E., & Ezquieta, B. (2006) · Endocrinología y Nutrición · doi:10.1016/s1575-0922(06)71078-6 · Cited by 5
Congenital adrenal hyperplasia owing to 21-hydroxylase deficiency
New, M. I., Lekarev, O., Jacob, M., Macdonald, A., Parsa, A. A., & Yuen, T. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821424-4.00031-9 · Cited by 4
Self-citationDiagnosis and management of congenital adrenal hyperplasia
Speiser, P. (2006) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.1.1.103 · Cited by 3
Hamaichat, M., Yacoubi, A. M. E., Moudden, S. E., & Abourazzak, S. (2025) · Cureus · doi:10.7759/cureus.83965 · Cited by 2
“Glucocorticoid treatment has also been observed to contribute to reduced final height by decreasing endogenous growth hormone (GH) secretion and insulin-like growth factor 1 bioactivity [9].”
Congenital Adrenal Hyperplasia
Nimkarn, S., & New, M. I. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374430-2.00015-8 · Cited by 2
Self-citationCongenital adrenal hyperplasia in adults
Lin‐Su, K., Nimkarn, S., & New, M. I. (2009) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.4.1.67 · Cited by 2
Self-citationGrowth pattern and pubertal development in patients with classic 21-hydroxylase deficiency
Bunraungsak, S., Klomchan, T., & Sahakitrungruang, T. (2013) · Asian Biomedicine · doi:10.5372/1905-7415.0706.241 · Cited by 3
“Recent studies showed that combined growth hormone plus GnRH analog are useful to improve final height in these patients [19, 20].”
BackgroundCongenital Adrenal Hyperplasia
Yau, M., Nimkarn, S., & New, M. I. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800892-8.00014-2 · Cited by 5
Self-citationAdrenogenital syndrome: past, present, and future
Kareva, M., & Орлова, Е. М. (2011) · Problems of Endocrinology · doi:10.14341/probl201157166-70 · Cited by 3
“В дополнение к глюкокортикоидной терапии было предложено использование препаратов гормона роста в сочетании с пролонгированными аналогами люлиберина с целью улучшения ростового прогноза пациентов [33].”
Deng, Y., Yang, N., Wang, J., & Tu, T. (2024) · Steroids · doi:10.1016/j.steroids.2024.109552 · Cited by 1
Dörr, H. (2010) · Elsevier eBooks · doi:10.1016/b978-3-437-24680-7.10030-3 · Cited by 3
Treatment and Outcome of Congenital Adrenal Hyperplasia: 21-Hydroxylase Deficiency
Lee, P. A., Fuqua, J. S., & Nebesio, T. D. (2010) · International Journal of Pediatric Endocrinology · doi:10.1155/2010/276843 · Cited by 1
Novas perspectivas no tratamento da hiperplasia adrenal congênita
Faria, J. A. D., Sampaio, D. S., Oliveira, L. M. B., Lago, R., Silva, C. N., Canguçú-Campinho, A. K., Schleu, M. F., & Toralles, M. B. P. (2010) · Revista de Ciências Médicas e Biológicas · doi:10.9771/cmbio.v9i3.5168
Nonclassic 21-Hydroxylase Deficiency and Short Stature in an Ethnically at-Risk Population
Agarwal, C., Hassoun, A. A., Aranoff, G. S., Pomeranz, C. B., & Oberfield, S. E. (2010) · The Endocrinologist · doi:10.1097/ten.0b013e3181e94b3c
Growth Hormone Therapy to Improve Adult Height in Patients with Congenital Adrenal Hyperplasia
Lin‐Su, K., Lekarev, O., & New, M. I. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-416006-4.00005-3
Self-citationNovel Therapies for Treating Short Stature with Congenital Adrenal Hyperplasia
Simpson, J. L., Hann, M., Kshetrapal, A., & New, M. I. (2011) · International Journal of Infertility & Fetal Medicine · doi:10.5005/jp-journals-10016-1017
“4 Inclusion criteria were: (1) age more than 4 years, (2) bone age more than 2.”
BackgroundSelf-citationAvaliação do crescimento e estatura final de pacientes com hiperplasia congenita de supra-renal
Kohara, S. K. (2007) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Hiperplasia da Supra-renal Complicada de Puberdade Precoce Central - Caso Clínico
Bandeira, A., Cardoso, H., & Borges, T. (2006) · Nascer e crescer
Children Consensus Statement on the Use of Gonadotropin-Releasing Hormone Analogs in
Carel, J., Eugster, E. A., Rogol, A. D., & Ghizzoni, L. (2012)
Longui, C. A., Kochi, C., Procópio, L. E., Modkovski, M. B. R., Soares, M., Alves, F., & Monte, O. (2011)
Aslih, N. (2014) · Reproductive System & Sexual Disorders · doi:10.4172/2161-038x.1000142
“Analysis of serum steroids may be confusing and nondiagnostic of the other CAH subtypes [55,56].”
BackgroundBarseem, N. F. (2016) · International Journal of Endocrinology and Metabolic Disorders · doi:10.16966/2380-548x.121
“We found that none of our CAH patients had true precocious puberty so, did not require treatment with GnRH analogue; a consequence of excess of adrenal androgens, leading to early activation of the hypothalamic pituitary gonadal axis and occurrence of secondary central precocious puberty [26,27].”
BackgroundCongenital adrenal hyperplasia
Daily, J. G., & Vigersky, R. A. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-4975-1.00040-1
Debates and Controversies in Genetic Steroid Disorders
Speiser, P. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-416006-4.00030-2
Dörr, H. G. (2015) · Elsevier eBooks · doi:10.1016/b978-3-437-22107-1.50270-3
Congenital Adrenal Hyperplasia
Baquero, J. A. G., & Vigersky, R. A. (2009) · Elsevier eBooks · doi:10.1016/b978-0-323-05885-8.00031-3
Endokrinologische Erkrankungen
(2011) · Elsevier eBooks · doi:10.1016/b978-3-437-22702-8.50013-3
(2006) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/01.med.0000202323.44809.4f
Congenital adrenal hyperplasia in children
Riepe, F. G. (2011) · doi:10.1093/med/9780199235292.003.7122
Debates and controversies in genetic steroid disorders
Speiser, P. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821424-4.00014-9
Growth hormone treatment in children with congenital adrenal hyperplasia
Lin‐Su, K., Lekarev, O., & New, M. I. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821424-4.00023-x
Self-citation
Metadata
- Authors
- Lin-Su, K., Vogiatzi, M. G., Marshall, I., Harbison, M. D., Macapagal, M. C., Betensky, B., Tansil, S., & New, M. I.
- Affiliations
- Cornell University (US)
- Rutgers, The State University of New Jersey (US)
- Icahn School of Medicine at Mount Sinai (US)
- Corresponding author
- New, Maria I.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2005-06
- Volume
- 90
- Issue
- 6
- Pages
- 3318-3325
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2046147708
- Cited by
- 111
- References
- 40
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 2 · 2023: 4 · 2021: 3 · 2020: 2 · 2019: 5 · 2018: 2 · 2016: 3 · 2015: 8 · 2014: 5 · 2013: 9 · 2012: 1
- FWCI
- 2.64
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Center for Research Resources (RR06020)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (HD 00072)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- congenital adrenal hyperplasia, 21-hydroxylase deficiency, growth hormone therapy, luteinizing hormone-releasing hormone analogue, adult height, short stature, glucocorticoid therapy, height prediction
- MeSH terms
- Adolescent, Adrenal Hyperplasia, Congenital, Adult, Body Height, Child, Female, Growth, Humans, Gonadotropin-Releasing Hormone, Male, Treatment Outcome, Human Growth Hormone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.